TB-500 (Thymosin Beta-4) · Research brief

What Is TB 500 Thymosin Beta 4? Fragment vs Full-Length

Real Peptides Research TeamEditorial

Updated September 28, 20269 min read

58 WORDS

Short answer

Two vials labelled TB-500 can hold two chemically different molecules, and nothing on the outside of the vial tells you which one you received. One is the complete 43-amino-acid peptide thymosin beta-4. The other is a short synthetic construct built around residues 17 to 23, the actin-binding stretch LKKTETQ. Same trade name. Same product photograph. Different molecular weight.

Key takeaways

Thymosin beta-4 is a 43-amino-acid, roughly 4.9 kDa actin-sequestering peptide encoded by the TMSB4X gene, and TB-500 is a research-chemical trade name applied to it.
The actin-binding domain sits at residues 17 to 23, the heptapeptide LKKTETQ, which is the region short fragment constructs reproduce.
Full-length material can release the N-terminal tetrapeptide Ac-SDKP via prolyl oligopeptidase; a 17-23 fragment cannot, because that region is absent.
Observed mass on a mass spectrometry report is the only reliable way to tell full-length material from a fragment construct.
The acetate designation on a label refers to the counterion from HPLC purification, which is why net peptide content differs from total vial mass.
Thymosin beta-4 and TB-500 are prohibited at all times in sport under the World Anti-Doping Agency list and are banned by equine racing authorities.

We source, test and ship research peptides for laboratory clients, and this identity question comes up more than any other in this category. The answer lives in the analytical data, never in the marketing copy.

What is TB 500 thymosin beta 4?

TB 500 thymosin beta 4 is a research-chemical trade name applied to synthetic thymosin beta-4, a 43-residue actin-sequestering peptide of roughly 4.9 kDa encoded by the TMSB4X gene. Some suppliers ship the full sequence; others ship a shortened acetylated fragment. Confirm the observed mass on the certificate of analysis before assuming which molecule is in the vial.

The common oversimplification is that TB-500 and thymosin beta-4 are interchangeable synonyms. They overlap, but the name is a label applied by vendors, not a chemical identity, and the peer-reviewed literature is written about thymosin beta-4 rather than about TB-500. This piece covers what the molecule actually is, how actin sequestration drives the reported activity, why the 17-23 fragment question changes one whole mechanistic pathway, and what a usable certificate of analysis has to show.

The molecule behind the trade name

Thymosin beta-4 is a 43-amino-acid peptide of approximately 4.9 kDa, one of the most abundant intracellular peptides in platelets, neutrophils, macrophages and many other cell types. It is N-terminally acetylated in vivo. It isn't a hormone and it isn't a classical growth factor. Its structural job is holding monomeric G-actin in a soluble, ready-to-use pool.

The trade name arrived later, out of the research-chemical market rather than out of pharmacology, and that is where the confusion begins. Some catalogues define the tb 500 thymosin beta 4 peptide as the complete 43-residue synthetic sequence. Others define it as an acetylated construct centred on the heptapeptide LKKTETQ at positions 17 to 23, sometimes listed as the tb 500 thymosin beta 4 fragment 17 23. Both are sold under the same three characters.

Salt form adds a third layer. Peptides purified by reversed-phase HPLC are typically ion-exchanged into an acetate salt, which is why labels read tb 500 thymosin beta 4 acetate. That acetate counterion plus residual bound water means the total mass in the vial is not all peptide, which is exactly why a certificate should state net peptide content alongside chromatographic purity.

In our experience reviewing incoming batch documentation, mislabelling is rarely deliberate. It is inherited. A distributor copies a description from an upstream supplier who copied it from someone else, and nobody rechecks the mass.

How one short actin-binding stretch drives so much of the literature

Thymosin beta-4 binds monomeric G-actin in a 1:1 complex and sequesters it, blocking spontaneous polymerisation into F-actin filaments. That sounds like a passive brake. It functions as a loaded spring. By maintaining a large reservoir of unpolymerised actin, the peptide lets a cell assemble filaments quickly and directionally at the leading edge, which is the physical basis for the cell migration, angiogenesis and tissue-repair activity reported throughout the thymosin beta-4 literature. Bock-Marquette and colleagues reported in Nature in 2004 that thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration and survival in animal models.

Here is the detail almost every product page omits. The N-terminal tetrapeptide Ac-SDKP, N-acetyl-seryl-aspartyl-lysyl-proline, is liberated from full-length thymosin beta-4 by prolyl oligopeptidase and carries its own reported antifibrotic and angiogenic activity in published work. A construct reproducing only residues 17 to 23 has no N-terminus to cleave. It cannot generate Ac-SDKP at all.

So the fragment question in tb 500 thymosin beta 4 sourcing is not pedantry about a mass spec readout. It decides whether an entire downstream pathway described in the literature can even occur in your model system. Research suggests the actin-binding motif accounts for much of the migratory activity, but the antifibrotic arm traces back to a region the fragment simply does not contain.

What a certificate of analysis has to show before identity is settled

A usable certificate answers three questions: what the molecule is, how pure it is, and which vial it belongs to. Identity comes from mass spectrometry, either ESI-MS or MALDI-TOF, with the observed mass reported against the theoretical mass. Full-length material lands near 4.9 kDa. Heptapeptide constructs land under 1 kDa. There is no ambiguity once that number is printed.

Purity comes from an HPLC chromatogram, not a typed percentage on a web page. Research-grade material is commonly specified at 98 percent or higher by area under the curve, and the trace should show a dominant single peak rather than a shoulder cluster. The lot number on the certificate must match the lot number on the vial, otherwise the document is decorative.

Handling is mundane and decides everything downstream. Lyophilised peptide is stored at minus 20 degrees Celsius, protected from light and moisture; once reconstituted, material is refrigerated at 2 to 8 degrees Celsius and treated as short-lived. Repeated freeze-thaw cycling degrades peptide integrity in ways that neither appearance nor solubility will reveal.

Because identity is the weak link in this category, every batch of TB-500 10mg we supply is small-batch synthesised with lot-matched analytical documentation available for review before purchase. Every compound discussed here is supplied strictly for laboratory research use, is not an FDA-approved drug, and is not intended for human or veterinary consumption.

TB 500 thymosin beta 4 versus the 17-23 fragment, side by side

This table compares what full-length material and short fragment constructs actually differ on, which matters because both are routinely sold under the same name. The differences that count are mass, pathway coverage and how well the published literature maps onto what is in the vial.

Attribute	Full-length thymosin beta-4 (43 residues)	Short 17-23 fragment constructs	Bottom line for the lab
Sequence and observed mass	43 amino acids, approximately 4.9 kDa, N-terminally acetylated	Core heptapeptide LKKTETQ, under 1 kDa, commonly acetylated	Mass spectrometry on the certificate resolves identity immediately; nothing else needs debating
G-actin sequestration	Binds monomeric actin in a 1:1 complex, maintaining the unpolymerised pool	Retains the binding motif, but binding behaviour of the isolated stretch is not equivalent to intact peptide	Published binding data was generated on full-length material, so citing it for a fragment overstates the evidence
Ac-SDKP generation	N-terminal tetrapeptide can be released by prolyl oligopeptidase	Impossible, the N-terminal region is absent from the construct	Any antifibrotic readout that depends on Ac-SDKP requires full-length material
Literature depth	Substantial peer-reviewed body, including ophthalmic clinical programmes investigating thymosin beta-4	Sparse and largely vendor-authored rather than peer-reviewed	Search and cite by molecule name, not by trade name
Typical labelling	Sold as thymosin beta-4, TB4, or the acetate salt form	Also sold as TB-500, sometimes with no sequence stated	The trade name carries no identity guarantee on its own

What If: TB-500 Sourcing and Handling Scenarios

What if the certificate lists an observed mass near 900 Da?

Treat that vial as a short fragment construct, not full-length thymosin beta-4. A mass in that range is consistent with an acetylated heptapeptide around the LKKTETQ region rather than the 43-residue sequence at approximately 4.9 kDa. Any experimental design that assumes the full sequence, particularly anything touching Ac-SDKP release, needs to be rewritten before work begins. Contact the supplier and ask them to state the sequence explicitly.

What if the listing shows 98 percent purity but no mass spectrometry data?

Purity without identity is an incomplete document. An HPLC percentage only tells you that one species dominates the sample; it says nothing about which species that is. A single clean peak of the wrong peptide still reads as high purity. Ask for the MS trace with theoretical and observed mass reported side by side, and confirm the lot number matches your vial before accepting the batch.

What if a supplier lists TB4 and TB-500 as two separate catalogue items?

That can be legitimate, but it requires the sequences to be published for both. Some vendors use TB4 for the full 43-residue sequence and reserve TB-500 for the shorter construct, which is a defensible convention. Others use the two names for identical material at different price points. The tb4 vs tb 500 question is answered by comparing the two certificates, not the two descriptions.

What if reconstituted material sat at room temperature overnight?

Document the excursion in the lab record and treat the vial as compromised for quantitative work. Reconstituted peptide is stored at 2 to 8 degrees Celsius, and degradation from a temperature excursion is invisible to inspection because the solution stays clear. Re-running analytical confirmation is the only way to know what remains, which usually costs more than replacing the vial.

What if a horse owner asks about TB-500 for a tendon injury?

Redirect the question to a licensed clinician rather than answering it. Anyone with an animal health question should talk to their veterinarian, because TB-500 has no veterinary approval, is banned by racing and equestrian authorities, and carries real regulatory consequences for competing animals. Research-grade peptides are laboratory materials supplied for research use only, not treatments, and they are never intended for administration to animals or people.

The unglamorous truth about TB-500 reviews

Let's be direct about this: there is no controlled human clinical trial of TB-500 as a product, and anyone presenting a tb 500 thymosin beta 4 review as clinical evidence is confusing anecdote with data. The credible research record belongs to thymosin beta-4 as a molecule, including corneal and cardiac repair work in animal and clinical settings, and that record was generated with characterised, full-length material at defined concentrations. Forum reviews measure sentiment, shipping speed and vial appearance. None of that is a purity assay. When you read a review, ask what it could possibly have measured.

The same evidence discipline applies across the wider catalogue, so alongside our TB-500 page and the related Thymosin Alpha-1 peptide, we publish certificates of analysis and list full specifications across the research peptide catalogue so identity can be verified before anything reaches a bench.

Everything genuinely interesting about tb 500 thymosin beta 4 comes from a 43-residue sequence that cells keep in enormous supply precisely because fast, directional actin assembly is so fundamental to repair. That biology is real and well documented. The trade name wrapped around it is not biology, it is inventory language, and it has drifted far enough from the molecule that two vials with identical labels can contain peptides differing fivefold in mass. Read the mass. The name was never the evidence.

References

Peer-reviewed sources on TB-500 (Thymosin Beta-4) indexed in PubMed, listed for research context. Real Peptides supplies TB-500 (Thymosin Beta-4) for laboratory research use only.

Thymosin β4 alleviates sepsis-associated acute kidney injury by suppressing MAPK signaling pathway. Clinical science (London, England : 1979), 2026. PMID 42417058. doi:10.1042/CS20261084
Sprayable bioadhesive microcarriers loaded with Tβ4-Engineered ADSC exosomes for diabetic wound healing. Bioactive materials, 2026. PMID 42383202. doi:10.1016/j.bioactmat.2026.06.024
Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids. Stem cell reports, 2025. PMID 40816274. doi:10.1016/j.stemcr.2025.102601
Mechanistic study of the Tβ4/SLC7A11 signaling pathway regulating breast cancer evolution. Cellular signalling, 2025. PMID 40912522. doi:10.1016/j.cellsig.2025.112111
Thymosin β4 Regulates Tissue Inflammatory Response in Mouse Nonalcoholic Fatty Liver Disease by Promoting Macrophage M2-Type Polarization. Journal of inflammation research, 2025. PMID 40322536. doi:10.2147/JIR.S492814
Injectable Thymosin β4-Modified Hyaluronic Acid Hydrogel with Exosomes for Stem Cell Homing and Neuronic-Angiogenic-Osteogenic Coupled Cranial Repair. ACS nano, 2025. PMID 40528381. doi:10.1021/acsnano.4c10386
Secreted Expression of Thymosin β4 from Pinctada fucata in Pichia pastoris and Its Biological Activity. Biology, 2025. PMID 40427742. doi:10.3390/biology14050553
Thymosin β4 and the anti-fibrotic switch. International immunopharmacology, 2023. PMID 36580759. doi:10.1016/j.intimp.2022.109628

Questions

TB 500 thymosin beta 4 is a research-chemical name for synthetic thymosin beta-4, a 43-amino-acid peptide of roughly 4.9 kDa encoded by the TMSB4X gene that sequesters monomeric G-actin. Depending on the supplier, the vial may contain the full sequence or a shorter acetylated construct built around residues 17 to 23.

Usually yes, but not always in full-length form. TB-500 is a trade name rather than a chemical identity, so it may denote complete synthetic thymosin beta-4 at approximately 4.9 kDa or a short fragment construct centred on the LKKTETQ actin-binding region. Only the observed mass on a mass spectrometry report settles it.

They are closely related but not automatically identical. Thymosin beta-4 is a defined 43-residue peptide with a published sequence; TB-500 is a market label applied to it and, at some suppliers, to a shortened 17-23 fragment instead. The certificate of analysis, not the product name, confirms which molecule arrived.

Thymosin beta-4 binds monomeric G-actin in a 1:1 complex, maintaining a reservoir of unpolymerised actin that cells draw on for rapid filament assembly. Research links this to cell migration, angiogenesis and tissue repair in laboratory and animal models. It is a research compound, not an approved therapy for any condition.

Safety has not been established, because TB-500 is not an FDA-approved drug and has not been evaluated in controlled human trials as a marketed product. It is supplied for laboratory research use only and is not intended for human or animal consumption. Anyone with an animal health question should talk to their veterinarian.

TB4 is shorthand for thymosin beta-4, the 43-amino-acid peptide itself. TB-500 is a vendor trade name that may refer to the same molecule or to a shorter fragment construct. Some catalogues sell both as separate items with different sequences, so compare the two certificates rather than the two descriptions.

Residues 17 to 23 form the heptapeptide LKKTETQ, the actin-binding domain of thymosin beta-4. Fragment constructs reproduce this stretch, often acetylated, at a mass under 1 kDa rather than the full 4.9 kDa sequence. They retain the binding motif but cannot generate the N-terminal tetrapeptide Ac-SDKP.

Lyophilised peptide is stored at minus 20 degrees Celsius, protected from light and moisture. Once reconstituted, the solution is refrigerated at 2 to 8 degrees Celsius and treated as short-lived, since repeated freeze-thaw cycling degrades peptide integrity invisibly. Log any temperature excursion, because clear solution appearance proves nothing about remaining potency.

Peptides purified by reversed-phase HPLC are commonly ion-exchanged into an acetate salt, which is why listings read thymosin beta-4 acetate. The acetate counterion and residual bound water mean total vial mass exceeds actual peptide mass, so a complete certificate reports net peptide content alongside chromatographic purity.

Research-grade peptides are supplied to researchers, laboratories and institutions for in-vitro and preclinical work, not to consumers for personal use. Pricing varies widely across suppliers depending on synthesis scale, purity specification and whether full analytical documentation is included. Cheaper material almost always reflects thinner characterisation rather than better sourcing.

Yes. Thymosin beta-4 and TB-500 are prohibited at all times under the World Anti-Doping Agency list covering peptide hormones, growth factors and related mimetics, and equine racing authorities ban it in competing horses. Detection methods exist, and regulatory consequences apply to both human and animal competition.

Reviews typically measure shipping speed, packaging and vial appearance, none of which indicate identity or purity. No controlled human clinical trial exists for TB-500 as a product, so anecdotal reports cannot substitute for analytical data. An HPLC chromatogram and a matching mass spectrometry trace carry far more information than any review.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA